Advertisement
DVAX vs INCR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a StrongBuy and INCR is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DVAX’s FA Score shows that 0 FA rating(s) are green whileINCR’s FA Score has 1 green FA rating(s).
- DVAX’s FA Score: 0 green, 5 red.
- INCR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DVAX’s TA Score shows that 5 TA indicator(s) are bullish while INCR’s TA Score has 5 bullish TA indicator(s).
- DVAX’s TA Score: 5 bullish, 3 bearish.
- INCR’s TA Score: 5 bullish, 4 bearish.
Price Growth
DVAX (@Pharmaceuticals: Other) experienced а +5.97% price change this week, while INCR (@Pharmaceuticals: Other) price change was +1.97% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.53%. For the same industry, the average monthly price growth was +11.98%, and the average quarterly price growth was +75.52%.
Reported Earning Dates
DVAX is expected to report earnings on Oct 30, 2025.
INCR is expected to report earnings on Nov 18, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (+3.53% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| DVAX | INCR | DVAX / INCR | |
| Capitalization | 1.62B | 124M | 1,307% |
| EBITDA | 9.67M | 25.8M | 37% |
| Gain YTD | -11.042 | -2.516 | 439% |
| P/E Ratio | 31.63 | 22.52 | 140% |
| Revenue | 232M | 415M | 56% |
| Total Cash | 742M | 103M | 720% |
| Total Debt | 257M | 163M | 158% |
DVAX | INCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 58 Fair valued | |
PROFIT vs RISK RATING 1..100 | 80 | 100 | |
SMR RATING 1..100 | 93 | 93 | |
PRICE GROWTH RATING 1..100 | 52 | 61 | |
P/E GROWTH RATING 1..100 | 97 | 3 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCR's Valuation (58) in the Servicestothe Health Industry industry is in the same range as DVAX (68) in the Biotechnology industry. This means that INCR’s stock grew similarly to DVAX’s over the last 12 months.
DVAX's Profit vs Risk Rating (80) in the Biotechnology industry is in the same range as INCR (100) in the Servicestothe Health Industry industry. This means that DVAX’s stock grew similarly to INCR’s over the last 12 months.
DVAX's SMR Rating (93) in the Biotechnology industry is in the same range as INCR (93) in the Servicestothe Health Industry industry. This means that DVAX’s stock grew similarly to INCR’s over the last 12 months.
DVAX's Price Growth Rating (52) in the Biotechnology industry is in the same range as INCR (61) in the Servicestothe Health Industry industry. This means that DVAX’s stock grew similarly to INCR’s over the last 12 months.
INCR's P/E Growth Rating (3) in the Servicestothe Health Industry industry is significantly better than the same rating for DVAX (97) in the Biotechnology industry. This means that INCR’s stock grew significantly faster than DVAX’s over the last 12 months.
| DVAX | INCR | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 88% | N/A |
| Stochastic ODDS (%) | 3 days ago 80% | 3 days ago 83% |
| Momentum ODDS (%) | 3 days ago 77% | 3 days ago 84% |
| MACD ODDS (%) | N/A | 3 days ago 77% |
| TrendWeek ODDS (%) | 3 days ago 73% | 3 days ago 77% |
| TrendMonth ODDS (%) | 3 days ago 73% | 3 days ago 71% |
| Advances ODDS (%) | 5 days ago 75% | 7 days ago 72% |
| Declines ODDS (%) | N/A | 5 days ago 80% |
| BollingerBands ODDS (%) | 3 days ago 83% | 3 days ago 87% |
| Aroon ODDS (%) | 3 days ago 76% | 3 days ago 75% |
Advertisement
INCR and
Correlation & Price change
A.I.dvisor tells us that INCR and SNDL have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INCR and SNDL's prices will move in lockstep.
| Ticker / NAME | Correlation To INCR | 1D Price Change % | ||
|---|---|---|---|---|
| INCR | 100% | +0.65% | ||
| SNDL - INCR | 25% Poorly correlated | -1.62% | ||
| ACB - INCR | 24% Poorly correlated | +0.62% | ||
| OGI - INCR | 24% Poorly correlated | +1.32% | ||
| DVAX - INCR | 23% Poorly correlated | +1.79% | ||
| SUPN - INCR | 23% Poorly correlated | +2.22% | ||
More | ||||